8-K: Revvity Q1 2026 Results: Divestiture of China IDX Business

Revvity, Inc. reported Q1 2026 financial results, including revenue growth and adjusted EPS, while announcing its strategic intent to divest its China Immunodiagnostics business.

Summary

• Revvity, Inc. announced its financial results for the first quarter ended April 5, 2026.
• The company reported GAAP earnings per share from continuing operations of $0.37 and revenue of $711 million.
• Adjusted earnings per share from continuing operations were $1.06.
• Revvity also announced its strategic decision to divest its Immunodiagnostics business in China (China IDX), which represented approximately 6% of its total revenue in fiscal year 2025.
• A letter of intent has been signed with a prospective buyer, with a definitive agreement expected in Q2 2026 and completion in 2027.
• Pro forma results, excluding the China IDX business, show Q1 2026 revenue of $687 million and pro forma adjusted EPS of $1.04.
• Full year 2026 pro forma guidance includes total revenue of $2.81-$2.84 billion, pro forma organic revenue growth of 3%-4%, and pro forma adjusted EPS of $5.20-$5.30.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive filing, with strong Q1 performance exceeding expectations and a clear strategic direction indicated by the divestiture, though some margin compression is noted.

Positives

• First quarter organic growth and adjusted EPS exceeded expectations.
• Revenue for the quarter was $711 million, an increase from $665 million in the prior year period.
• GAAP EPS from continuing operations increased to $0.37 from $0.35 in the prior year period.
• Adjusted EPS from continuing operations increased to $1.06 from $1.01 in the prior year period.
• Pro forma adjusted EPS from continuing operations increased to $1.04 from $0.95 in the prior year period.
• Life Sciences segment revenue increased 6% year-over-year.
• Diagnostics segment revenue increased 8% year-over-year.
• Full year 2026 pro forma adjusted EPS guidance is projected to be between $5.20 and $5.30.

Negatives

• GAAP operating profit margin from continuing operations decreased slightly to 10.7% from 10.9% in the prior year period.
• Adjusted operating profit margin decreased to 23.6% from 25.6% in the prior year period.
• Pro forma adjusted operating profit margin decreased to 24.0% from 25.3% in the prior year period.
• The divestiture of the China IDX business, while strategic, represents a reduction in the company's overall revenue base.

Risks

• The company's ability to execute acquisitions and divestitures.
• Markets into which the company sells its products may decline or not grow as anticipated.
• Fluctuations in the global economic and political environments.
• Failure to introduce new products in a timely manner.
• Difficulties in successfully integrating acquired businesses or making them profitable.
• Disruptions in the supply of raw materials and supplies.
• Uncertainties related to the development and use of AI in product offerings and internal operations.
• Regulatory changes and compliance with healthcare industry regulations.

Future Outlook

For the full year 2026, Revvity forecasts total revenue on a pro forma basis to be between $2.81 billion and $2.84 billion. Pro forma organic revenue growth is expected to be between 3% and 4%, and pro forma adjusted earnings per share are projected to be between $5.20 and $5.30.

Management Comments

• "We performed well in the first quarter, with organic growth and adjusted EPS exceeding our expectations, reflecting strong execution from our teams across the organization."
• "Our disciplined approach to portfolio optimization positions us well to capitalize on improving market conditions and deliver differentiated results for shareholders."

Industry Context

StockSavvy.ai notes that Revvity's strategic divestiture of its China Immunodiagnostics business aligns with broader industry trends of portfolio optimization and focus on core competencies, particularly in the health sciences sector where specialization is key to innovation and market leadership.

Comparison to Industry Standards

• The reported Q1 2026 revenue growth of 7% and organic growth of 3% are solid, but need to be compared against specific sub-segments within the health sciences and diagnostics industries to determine if they meet or exceed industry benchmarks.
• The adjusted EPS of $1.06 for Q1 2026 demonstrates profitability, but its comparison to industry peers like Thermo Fisher Scientific or Danaher would require detailed analysis of their respective reporting periods and non-GAAP adjustments.
• The pro forma organic growth of 6% in Diagnostics is a strong indicator, suggesting resilience and potential outperformance in that segment compared to broader market trends for diagnostic tools and services.

Stakeholder Impact

• Shareholders: Potential for increased focus and efficiency from divestiture, alongside improved financial performance metrics. The guidance suggests continued growth.
• Employees: The divestiture of the China IDX business may impact employees within that specific unit. Employees in other segments are expected to benefit from the company's strategic focus.
• Customers: Continued provision of health science solutions and technologies. The divestiture may lead to a more focused product and service offering.
• Suppliers: Potential changes in supply chain dynamics related to the divested business. Core operations are expected to continue with existing supplier relationships.

Next Steps

• Sign a definitive agreement for the sale of the China IDX business in Q2 2026.
• Complete the divestiture of the China IDX business in 2027, subject to regulatory approvals.
• Continue to execute on the company's strategic portfolio optimization.
• Deliver differentiated results for shareholders.

Key Dates

Recommendation

The company delivered expected results with some positive surprises in organic growth and EPS, and is taking strategic steps to optimize its portfolio. However, the divestiture introduces some uncertainty, and the guidance, while positive, is in line with expectations. A 'hold' recommendation reflects a balanced view of current performance and future strategic execution.

Keywords

Revvity, 8-K, Q1 2026, Financial Results, Divestiture, China Immunodiagnostics, Pro Forma, Guidance